Lerdelimumab

Lerdelimumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	TGF beta 2
Clinical data
ATC code	none;
Legal status
Legal status	Development discontinued;
Identifiers
CAS Number	285985-06-0 ;
ChemSpider	none;
UNII	GX1FEU3QSM;
	(what is this?)

Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.

It was being developed to reduce scarring after glaucoma drainage surgery.^[1] Development was stopped in late 2005 after unsuccessful trial results for that condition.^[2]

References[]

^ "Lerdelimumab". Drugs in R&D. 3 (2): 106–8. 1 February 2002. doi:10.2165/00126839-200203020-00006. PMID 12001808.
^ "CAT abandons Trabio after second clinical trial failure". The Pharma Letter. 28 March 2005.

This monoclonal antibody–related article is a stub. You can help Wikipedia by .

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[1] "Lerdelimumab". Drugs in R&D. 3 (2): 106–8. 1 February 2002. doi:10.2165/00126839-200203020-00006. PMID 12001808.

[2] "CAT abandons Trabio after second clinical trial failure". The Pharma Letter. 28 March 2005.

[1]

[2]